

## DIASTEREOSELECTIVE SYNTHESIS OF CYCLOPROPYL PHENYLALANINES AND THEIR INCORPORATION INTO DIPEPTIDES

Malcolm M. Campbell<sup>a</sup>, David C. Horwell<sup>\*b</sup>, Mary F. Mahon<sup>a</sup>,  
Martyn C. Pritchard<sup>b</sup> and Steven P. Walford<sup>a</sup>


<sup>a</sup>School of Chemistry, University of Bath, Bath, BA2 7AY.

<sup>b</sup>Parke-Davis Neuroscience Research Unit, Addenbrookes Hospital Site, Hills Road, Cambridge, CB2 2QB.

(Received in USA 8 December 1992)


**Abstract:** 2,3-Methanophenylalanine methyl esters have been prepared diastereoselectively and incorporated into dipeptoid analogues of the tetrapeptide cholecystokinin, CCK(30-33). (Z)-(1S, 3S, 6S)- and (E)-(1R, 3S, 6S)-7(H)-6-isopropyl- 5-methoxy-1-phenyl-4,7-diazaspiro[2,5]oct-4-en-8-ones (**12a,b**) have been hydrolysed to afford the (Z)- and (E)-  $\nabla$ Phe-Val-OMe dipeptides (**16a,b**), respectively.

The dehydropeptides, N <sup>$\alpha$</sup> -(2-Adoc)-R- $\alpha$ -Me-Trp- $\Delta^Z$ Phe-OR (**1**, R=Me); and (**2**, R=H)<sup>1</sup> have recently been identified as dipeptoid mimetics of CCK-4 (CCK(30-33)).<sup>2a,b</sup> The carboxylic acid (**2**) was found to have 60 and 54nm affinity for the CCK-A and CCK-B receptors respectively (see Table 1). The corresponding E-isomers were not obtainable.



(**1**, R= Me; **2**, R= H)

Consequently, it was decided to synthesise the cyclopropyl analogues of (**1**) and (**2**) via the replacement of the dehydrophenylalanine moiety with each of the (Z)- and (E)-2,3-methanophenylalanines (**3**) to give the cyclopropyl dipeptides (**4**) and (**5**), in order further to probe requirements for affinity at the CCK-A and CCK-B receptors.




(**3**, R= Me)

(**4**, R= Me; **5**, R= H)

In this communication we describe the synthesis of 2,3-methanophenylalanine methyl esters (**3**), the preparation and binding affinities of the cyclopropyl dipeptides (**4**) and (**5**), together with the preparation of other cyclopropyl dipeptides.

In the synthesis of 2,3-methanophenylalanine methyl esters (**3**) our methodology was based on a modification of Schöllkopf's bislactim ether approach<sup>3</sup>, utilizing a chiral diketopiperazine template (**8**) (Scheme 1). Diketopiperazine (**8**) was bisacylated to generate (**9**) in 60% yield. Treatment of (**9**) with potassium t-butoxide and benzaldehyde afforded mainly the monoacylated (*Z*)-benzylidene (**10a**) (*Z*:*E*, 9:1) in excellent yield (90%). The two geometrical isomers (**10a,b**)<sup>4</sup> were easily separated by flash chromatography and served as intermediate to both (*Z*)- and (*E*)-2,3-methanophenylalanine methyl esters (**3a,b**). The relative stereochemistry of each benzylidene isomer of (**10**) was ascertained by nmr experiments (n.O.e.). The (*Z*)-benzylidene (**10a**) was then treated with diazomethane to give directly a 4:1 mix of diastereomeric spirocyclopropanes (**11**), without any isolation of the pyrazoline intermediate, but in low yield (20%). These diastereomers were separable by flash chromatography and the major component (**11a**) was deacylated by treatment with potassium carbonate to give (**12a**) quantitatively. Spirocyclopropane (**12a**) was then converted to the bislactim ether (**13a**) (70%) with Meerwein's reagent and hydrolysed under mild conditions to generate the desired ester (**3a**) as a colourless oil in 58% yield.


### Scheme 1



*Reagents and conditions* : **i**, phosgene, tetrahydrofuran (THF), 40°C, 4h; **ii**, glycine ethyl ester hydrochloride, Et<sub>3</sub>N, CHCl<sub>3</sub>, -78°C, 1.5h; **7**, THF, -78°C, 3h; **iii**, PhCH<sub>3</sub>, reflux, 12h; **iv**, Ac<sub>2</sub>O, 110°C, 7h; **v**, **9**, benzaldehyde, DMF, 0°C, *t*-BuOK, THF, 0°C, 12h; **vi**, CH<sub>2</sub>N<sub>2</sub>, ether, room temp., 48h; **vii**, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>OH, 0°C, 15 mins.; **viii**, Me<sub>3</sub>OBf<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temp., 24h; **ix**, 0.25M HCl, ether 0°C, 12h; **x**, NH<sub>4</sub>OH, ether, 0°C.

The stereochemistry of (**3a**) was determined via obtaining a crystal structure of the *N*-tosyl derivative (**14a**). It was found to be (2*S*,3*S*) as expected (Figure 1).


Figure 1. X-ray Crystal Structure of 14a



This procedure was repeated for E-benzylidene (10b) giving similar yields to generate the (E)-2,3-methanophenylalanine methyl ester (3b) as a colourless oil in 60% yield. The cyclopropyl dipeptides (4) and (5) were prepared via Stammer's procedure<sup>5</sup> of coupling 2,3- methanophenylalanine methyl esters (Scheme 2). The N<sup>α</sup>-(2-Adoc)-R-α-methyl-tryptophan (15) was treated with *iso*-butyl chloroformate and N-methylmorpholine followed by a solution of (3a) to generate the desired product N<sup>α</sup>-(2-Adoc)-R-α-Me-Trp-(2S,3S)∇<sup>Z</sup>Phe-OMe (4a) in 45%

yield. The ester (4a) was then hydrolysed under mild basic conditions to afford the desired N<sup>α</sup>-(2-Adoc)-R-α-Me-Trp-(2S,3S)∇<sup>Z</sup>Phe-OH (5a) (50%).

Scheme 2



Abbreviation : 2-Adoc = 2-Adamantylloxycarbonyl; NMM = N-methylmorpholine.

Reagents and conditions . i, *isobutyl chloroformate*, NMM, THF, room temp., 1h; ii, (2S,3S)-(Z)-2,3-methanophenylalanine methyl ester, THF, room temp., 24h; iii, 0.1M NaOH, EtOH, reflux, 3h.

Table 1. CCK Receptor Binding Affinities<sup>a</sup>

No.	Compound	R	IC <sub>50</sub> , nM		
			CCK-A	CCK-B	A/B ratio
1	N <sup>α</sup> -(2-Adoc)-R-α-Me-Trp-Δ <sup>Z</sup> Phe-OR	Me	- <sup>b</sup>	270	-
2	"	H	60	54	1.1
4a	N <sup>α</sup> -(2-Adoc)-R-α-Me-Trp-(2S,3S)∇ <sup>Z</sup> Phe-OR	Me	720	600	1.2
5a	"	H	84	140	0.6
4b	N <sup>α</sup> -(2-Adoc)-R-α-Me-Trp-(2S,3R)∇ <sup>E</sup> Phe-OR	Me	26	3.9	6.7
	CCK(26-33) (Sulphated)	-	0.1	0.3	0.3


<sup>a</sup>IC<sub>50</sub> represents the concentration (nM) producing half-maximal inhibition of specific binding of [<sup>125</sup>I] Bolton Hunter CCK-8 to CCK receptors in the mouse cerebral cortex (CCK-B) or the rat pancreas (CCK-A). At the concentration of the iodinated radioligand used (35pm), in relation to its K<sub>D</sub> (350pm), the Cheng and Prussoff correction was insignificant and the IC<sub>50</sub> was taken as a measure of the apparent binding affinity (K<sub>i</sub>) of the compounds.

<sup>b</sup>Not measured.

The  $IC_{50}$  values given in Table 1 illustrate the importance of stereochemistry of the cyclopropane in determining CCK-A/CCK-B ratio, and that the preferred stereochemistry in **4b** gives a compound with an  $IC_{50}=3.9nM$  at the CCK-B receptor, indicating an 100-fold increase in affinity over its diastereomeric form (**4a**).

The tetrahydropyrazinones (**12a**) and (**12b**) were partially hydrolysed with 0.1M hydrochloric acid to give the dipeptides  $\nabla^Z$ Phe-Val-OMe (**16a**) and  $\nabla^E$ Phe-Val-OMe (**16b**) respectively in quantitative yields (Scheme 3).<sup>6</sup>

### Scheme 3



Reagents and conditions : i, 0.1M HCl,  $CH_3CN$ , room temp., 24h.

We have therefore developed a new diastereoselective synthesis of cyclopropyl amino acids and derived dipeptides which complement other recent procedures.<sup>7-9</sup>

### References and Notes:

1. The symbols  $\nabla$  and  $\Delta$  are as defined by Stammer, C.H. *Tetrahedron*, **1990**, 46, 2231, which states:- "The symbol  $\nabla^Z$  or  $\nabla^E$  prefixed to the abbreviation for an amino acid residue as in  $\nabla^Z$ Phe, means the Z-diastereomer of 2,3-methano- or cyclopropane-phenylalanine. It is used here only when the methanoamino acid appears in a peptide chain. The  $\Delta^Z$  symbol indicates a dehydroamino acid as a  $\Delta^Z$ Phe, meaning (Z)-2,3-dehydrophenylalanine."
2. (a) Horwell, D.C. EP 405 537/1991 : C.A., **115**, 50307; (b) Peptoid: as defined by Horwell, D.C.; Birchmore, B.R.; Boden, P.R.; Higginbottom, M.; Ping Ho, Y.; Hughes, J.; Hunter J.C.; Richardson, R.S. *Eur. J. Med. Chem.*, **1990**, 25, 53.
3. (a) Schöllkopf, U. *Tetrahedron*, **1983**, 39, 2085; (b) Schöllkopf, U. *Pure Appl. Chem.*, **1983**, 55, 1799; (c) Schöllkopf, U. *Top. Curr. Chem.*, **1983**, 109, 65.
4. **a** refers to Z-configuration, and **b** refers to E-configuration.
5. Mapelli, C.; Kimura H.; Stammer, C.H. *Int. J. Pept. Protein Res.*, **1986**, 28, 347.
6. Schöllkopf, U. DE 3 831 716/1988 : C.A., **113**, 115879.
7. Williams, R.M.; Fegley, G.J. *J. Am. Chem. Soc.*, **1991**, 113, 8796.
8. Fernández, D.; de Frutos, P.; Marco, J.L.; Fernández-Alvarez, E.; Bernabé, M. *Tetrahedron Lett.*, **1989**, 30, 3101.
9. Alcaraz, C.; Herrero, A.; Marco, J.L.; Fernández-Alvarez, E.; Bernabé, M. *Tetrahedron Lett.*, **1992**, 33, 5605.